Taro Pharmaceutical Industries Ltd. (TARO)
(Delayed Data from NYSE)
$107.44 USD
+0.88 (0.83%)
Updated May 3, 2019 04:02 PM ET
After-Market: $107.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$107.44 USD
+0.88 (0.83%)
Updated May 3, 2019 04:02 PM ET
After-Market: $107.36 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
by Zacks Equity Research
Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
by Zacks Equity Research
Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.
Procaps Group, S.A. (PROC) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Procaps Group, S.A. (PROC) delivered earnings and revenue surprises of 60% and 7.26%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate
by Zacks Equity Research
The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
by Zacks Equity Research
Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program
by Zacks Equity Research
Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.
Taro (TARO) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Taro (TARO) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
All You Need to Know About Taro (TARO) Rating Upgrade to Strong Buy
by Zacks Equity Research
Taro (TARO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Taro Pharmaceutical (TARO) Tops Q2 Earnings Estimates
by Zacks Equity Research
Taro (TARO) delivered earnings and revenue surprises of 111.11% and 8.03%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Taro Pharmaceutical (TARO) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Taro (TARO) delivered earnings and revenue surprises of -78.16% and 14.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Taro Pharmaceutical (TARO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Taro (TARO) delivered earnings and revenue surprises of -108.33% and 18.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
IsoRay (ISR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
IsoRay (ISR) delivered earnings and revenue surprises of 0% and 13.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Taro Pharmaceutical (TARO) Lags Q1 Earnings Estimates
by Zacks Equity Research
Taro (TARO) delivered earnings and revenue surprises of -56.47% and 4.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 55.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of -9.09% and 1.31%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
PolarityTE, Inc. (PTE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
PolarityTE, Inc. (PTE) delivered earnings and revenue surprises of -25% and 12.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
ProPhase Labs, Inc. (PRPH) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 74.36% and 95.52%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CASI Pharmaceuticals, Inc. (CASI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
CASI Pharmaceuticals, Inc. (CASI) delivered earnings and revenue surprises of 40% and 0.96%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Radius Health (RDUS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Radius Health (RDUS) delivered earnings and revenue surprises of -85.71% and 16.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Lags Q1 Earnings Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -57.58% and 1.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Taro Pharmaceutical (TARO) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Taro (TARO) delivered earnings and revenue surprises of -23.08% and 2.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Taro Pharmaceutical (TARO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taro (TARO) Surges 6.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Taro (TARO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Taro Pharmaceutical (TARO) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Taro (TARO) delivered earnings and revenue surprises of -35.29% and -13.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Taro Pharmaceutical (TARO) Q2 Earnings Expected to Decline
by Zacks Equity Research
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.